Agilent Technologies, Inc. (A) P/E Ratio History
Fairly ValuedTrading at 27.8x, near 5Y avg of 31.6x · 20th percentile · In line with own history · Data 2000–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Agilent Technologies, Inc. (A) trades at a price-to-earnings ratio of 27.8x, with a stock price of $127.06 and trailing twelve-month earnings per share of $4.98.
The current P/E is 12% below its 5-year average of 31.6x. Over the past five years, A's P/E has ranged from a low of 23.2x to a high of 47.9x, placing the current valuation at the 20th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, A trades at a 26% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 1.89 (P/E divided by 3% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, A trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our A DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
A Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
A P/E vs Peers
Life Science Instruments and Sequencing Tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $23B | 33.0 | 6.38 | +0% | |
| $173B | 26.2 | 12.40 | +7% | |
| $125B | 35.2 | - | -5% | |
| $23B | 27.1 | 2.45Best | +4% | |
| $8B | 10.1Lowest | - | +143% | |
| $7B | 153.5 | - | +287%Best | |
| $45B | 43.0 | 3.01 | +23% | |
| $25B | 29.7 | 7.02 | +171% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
A Historical P/E Data (2000–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $115.55 | $4.98 | 23.2x | -16% |
| FY2026 Q1 | Jan 31 2026 | $133.85 | $4.53 | 29.5x | +7% |
| FY2025 Q4 | Oct 31 2025 | $146.36 | $4.57 | 32.0x | +16% |
| FY2025 Q3 | - | $114.81 | $4.26 | 27.0x | -2% |
| FY2025 Q2 | Apr 30 2025 | $107.60 | $4.05 | 26.6x | -4% |
| FY2025 Q1 | Jan 31 2025 | $151.52 | $4.35 | 34.8x | +26% |
| FY2024 Q4 | - | $130.31 | $4.42 | 29.5x | +7% |
| FY2024 Q3 | Jul 31 2024 | $141.40 | $4.82 | 29.3x | +6% |
| FY2024 Q2 | - | $137.04 | $4.23 | 32.4x | +17% |
| FY2024 Q1 | Jan 31 2024 | $130.10 | $4.20 | 31.0x | +12% |
| FY2023 Q4 | - | $103.37 | $4.21 | 24.6x | -11% |
| FY2023 Q3 | Jul 31 2023 | $121.77 | $3.82 | 31.9x | +15% |
| FY2023 Q2 | Apr 30 2023 | $135.43 | $4.54 | 29.8x | +8% |
| FY2023 Q1 | - | $152.08 | $4.43 | 34.3x | +24% |
| FY2022 Q4 | Oct 31 2022 | $138.35 | $4.17 | 33.2x | +20% |
| FY2022 Q3 | Jul 31 2022 | $134.10 | $4.39 | 30.5x | +11% |
| FY2022 Q2 | Apr 30 2022 | $119.27 | $4.15 | 28.7x | +4% |
| FY2022 Q1 | Jan 31 2022 | $139.32 | $3.94 | 35.4x | +28% |
| FY2021 Q4 | Oct 31 2021 | $157.49 | $3.94 | 40.0x | +45% |
| FY2021 Q3 | Jul 31 2021 | $153.23 | $3.20 | 47.9x | +73% |
| FY2021 Q2 | Apr 30 2021 | $133.64 | $2.98 | 44.8x | +62% |
| FY2021 Q1 | Jan 31 2021 | $120.17 | $2.60 | 46.2x | +67% |
| FY2020 Q4 | Oct 31 2020 | $102.09 | $2.30 | 44.4x | +61% |
| FY2020 Q3 | Jul 31 2020 | $96.33 | $2.21 | 43.6x | +58% |
| FY2020 Q2 | - | $76.66 | $2.17 | 35.3x | +28% |
| FY2020 Q1 | Jan 31 2020 | $82.56 | $2.42 | 34.1x | +24% |
| FY2019 Q4 | - | $75.75 | $3.36 | 22.5x | -18% |
| FY2019 Q3 | Jul 31 2019 | $69.41 | $3.34 | 20.8x | -25% |
| FY2019 Q2 | - | $78.50 | $3.47 | 22.6x | -18% |
| FY2019 Q1 | - | $76.05 | $3.53 | 21.5x | -22% |
| FY2018 Q4 | Oct 31 2018 | $64.79 | $0.97 | 66.8x | +142% |
| FY2018 Q3 | - | $66.04 | $0.92 | 71.8x | +160% |
| FY2018 Q2 | Apr 30 2018 | $65.74 | $0.73 | 90.1x | +226% |
| FY2018 Q1 | Jan 31 2018 | $73.43 | $0.60 | 122.4x | +343% |
| FY2017 Q4 | - | $68.03 | $2.11 | 32.2x | +17% |
| FY2017 Q3 | Jul 31 2017 | $59.79 | $1.94 | 30.8x | +12% |
| FY2017 Q2 | Apr 30 2017 | $55.05 | $1.78 | 30.9x | +12% |
| FY2017 Q1 | - | $48.97 | $1.56 | 31.4x | +14% |
| FY2016 Q4 | Oct 31 2016 | $43.57 | $1.40 | 31.1x | +13% |
| FY2016 Q3 | Jul 31 2016 | $48.11 | $1.44 | 33.4x | +21% |
| FY2016 Q2 | Apr 30 2016 | $40.92 | $1.40 | 29.2x | +6% |
| FY2016 Q1 | Jan 31 2016 | $37.65 | $1.37 | 27.5x | -1% |
| FY2015 Q4 | Oct 31 2015 | $37.76 | $1.20 | 31.5x | +14% |
| FY2015 Q3 | Jul 31 2015 | $40.95 | $0.80 | 50.9x | +84% |
| FY2015 Q2 | - | $41.37 | $0.89 | 46.3x | +68% |
| FY2015 Q1 | Jan 31 2015 | $37.77 | $0.76 | 49.4x | +79% |
| FY2014 Q4 | Oct 31 2014 | $39.53 | $1.15 | 34.3x | +24% |
| FY2014 Q3 | - | $40.11 | $1.76 | 22.8x | -17% |
| FY2014 Q2 | Apr 30 2014 | $38.64 | $1.82 | 21.2x | -23% |
| FY2014 Q1 | Jan 31 2014 | $41.58 | $2.18 | 19.1x | -31% |
| FY2013 Q4 | - | $36.30 | $2.11 | 17.2x | -38% |
| FY2013 Q3 | Jul 31 2013 | $31.99 | $2.68 | 11.9x | -57% |
| FY2013 Q2 | - | $29.63 | $2.88 | 10.3x | -63% |
| FY2013 Q1 | - | $32.02 | $3.12 | 10.3x | -63% |
| FY2012 Q4 | Oct 31 2012 | $25.74 | $3.26 | 7.9x | -71% |
| FY2012 Q3 | - | $27.38 | $2.88 | 9.5x | -66% |
| FY2012 Q2 | Apr 30 2012 | $30.16 | $3.11 | 9.7x | -65% |
| FY2012 Q1 | - | $30.37 | $2.95 | 10.3x | -63% |
| FY2011 Q4 | Oct 31 2011 | $26.51 | $2.84 | 9.3x | -66% |
| FY2011 Q3 | Jul 31 2011 | $30.15 | $2.84 | 10.6x | -62% |
| FY2011 Q2 | Apr 30 2011 | $35.69 | $2.50 | 14.3x | -48% |
| FY2011 Q1 | Jan 31 2011 | $29.91 | $2.25 | 13.3x | -52% |
| FY2010 Q4 | Oct 31 2010 | $24.89 | $1.93 | 12.9x | -53% |
| FY2010 Q3 | Jul 31 2010 | $19.97 | $1.18 | 16.9x | -39% |
| FY2010 Q2 | Apr 30 2010 | $25.93 | $0.55 | 47.5x | +72% |
| FY2009 Q3 | Jul 31 2009 | $16.60 | $0.49 | 33.5x | +21% |
| FY2009 Q2 | - | $13.06 | $1.00 | 13.1x | -53% |
| FY2009 Q1 | Jan 31 2009 | $12.93 | $1.76 | 7.3x | -73% |
| FY2008 Q4 | Oct 31 2008 | $15.87 | $1.89 | 8.4x | -70% |
| FY2008 Q3 | - | $25.79 | $1.70 | 15.2x | -45% |
| FY2008 Q2 | Apr 30 2008 | $21.60 | $1.70 | 12.7x | -54% |
| FY2008 Q1 | - | $24.21 | $1.53 | 15.8x | -43% |
| FY2007 Q4 | Oct 31 2007 | $26.35 | $1.58 | 16.7x | -40% |
| FY2007 Q3 | - | $27.28 | $1.33 | 20.5x | -26% |
| FY2007 Q2 | Apr 30 2007 | $24.58 | $1.42 | 17.3x | -37% |
| FY2007 Q1 | Jan 31 2007 | $22.88 | $1.38 | 16.6x | -40% |
| FY2006 Q4 | - | $23.99 | $6.85 | 3.5x | -87% |
| FY2006 Q3 | Jul 31 2006 | $19.16 | $6.68 | 2.9x | -90% |
| FY2006 Q2 | Apr 30 2006 | $25.89 | $6.35 | 4.1x | -85% |
| FY2006 Q1 | - | $22.85 | $6.28 | 3.6x | -87% |
| FY2005 Q4 | Oct 31 2005 | $21.57 | $0.66 | 32.7x | +18% |
| FY2005 Q3 | Jul 31 2005 | $17.68 | $0.76 | 23.3x | -16% |
| FY2005 Q2 | Apr 30 2005 | $13.98 | $0.75 | 18.6x | -33% |
| FY2005 Q1 | Jan 31 2005 | $14.90 | $0.77 | 19.4x | -30% |
| FY2004 Q4 | Oct 31 2004 | $16.88 | $0.70 | 24.1x | -13% |
| FY2004 Q3 | Jul 31 2004 | $16.04 | $0.58 | 27.8x | +1% |
| FY2001 Q4 | Oct 31 2001 | $15.00 | $0.38 | 39.5x | +43% |
| FY2001 Q3 | - | $19.28 | $0.72 | 26.8x | -3% |
| FY2001 Q2 | Apr 30 2001 | $26.28 | $1.54 | 17.1x | -38% |
| FY2001 Q1 | Jan 31 2001 | $36.75 | $1.69 | 21.7x | -21% |
| FY2000 Q4 | - | $31.20 | $1.66 | 18.8x | -32% |
Average P/E for displayed period: 27.6x
Full Stock Analysis
Deep dive into A consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
26+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
A — Frequently Asked Questions
Quick answers to the most common questions about buying A stock.
What is A's P/E ratio?
Agilent Technologies, Inc. (A) trailing twelve-month P/E ratio is 27.8x, based on TTM diluted EPS of $4.98. The 5-year average P/E is 31.6x and the historical range spans 23.2x to 47.9x.
Is A stock overvalued or undervalued?
A trades at 27.8x P/E, near its 5-year average of 31.6x. The 20th percentile ranking within the 23.2x–47.9x historical range places valuation within normal bounds.
Is A stock expensive?
A is fairly valued relative to its own history. The current P/E of 27.8x is near the 5-year average of 31.6x (20th percentile of historical range).
What is A's historical P/E range?
Over the past 5 years, A's P/E ratio has ranged from 23.2x to 47.9x, with a median of 31.0x and an average of 31.6x. The current P/E of 27.8x places the stock at the 20th percentile of this range. Full historical data spans 2000–2026.
How does A's P/E compare to the S&P 500?
A trades at 27.8x P/E versus the S&P 500 median of 24.4x. The 14% premium to the market typically reflects higher expected earnings growth or quality.
How does A's valuation compare to Healthcare peers?
Agilent Technologies, Inc. P/E of 27.8x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is A's PEG ratio?
A PEG ratio is 1.89, based on a P/E of 27.8x and EPS growth of 3.2%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is A's earnings yield?
A earnings yield is 3.60%, the inverse of its 27.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.